Corvus Pharmaceuticals Stock Current Valuation
| CRVS Stock | USD 2.16 0.05 2.37% |
Valuation analysis of Corvus Pharmaceuticals helps investors to measure Corvus Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 80.6 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.31) in 2024. Fundamental drivers impacting Corvus Pharmaceuticals' valuation include:
Price Book 1.9395 | Enterprise Value 114 M | Enterprise Value Ebitda (2.12) |
Undervalued
Today
Please note that Corvus Pharmaceuticals' price fluctuation is risky at this time. Calculation of the real value of Corvus Pharmaceuticals is based on 3 months time horizon. Increasing Corvus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Corvus Pharmaceuticals is useful when determining the fair value of the Corvus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Corvus Pharmaceuticals. Since Corvus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Corvus Stock. However, Corvus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.16 | Real 3.27 | Target 7.1 | Hype 2.15 | Naive 1.82 |
The real value of Corvus Stock, also known as its intrinsic value, is the underlying worth of Corvus Pharmaceuticals Company, which is reflected in its stock price. It is based on Corvus Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Corvus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Corvus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Corvus Pharmaceuticals helps investors to forecast how Corvus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Corvus Pharmaceuticals more accurately as focusing exclusively on Corvus Pharmaceuticals' fundamentals will not take into account other important factors: Corvus Pharmaceuticals Company Current Valuation Analysis
Corvus Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Corvus Pharmaceuticals Current Valuation | 114.02 M |
Most of Corvus Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corvus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Corvus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Corvus Pharmaceuticals is extremely important. It helps to project a fair market value of Corvus Stock properly, considering its historical fundamentals such as Current Valuation. Since Corvus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corvus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corvus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Corvus Pharmaceuticals has a Current Valuation of 114.02 M. This is 99.21% lower than that of the Biotechnology sector and 97.55% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.31% higher than that of the company.
Corvus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corvus Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corvus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corvus Pharmaceuticals by comparing valuation metrics of similar companies.Corvus Pharmaceuticals is currently under evaluation in current valuation category among related companies.
Corvus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Corvus Pharmaceuticals from analyzing Corvus Pharmaceuticals' financial statements. These drivers represent accounts that assess Corvus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Corvus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 159.7M | 104.9M | 100.9M | 39.6M | 84.5M | 140.7M | |
| Enterprise Value | 157.7M | 90.8M | 41.1M | 29.0M | 73.3M | 80.6M |
Corvus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corvus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corvus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Corvus Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 114.02 M | ||||
| Shares Outstanding | 62.55 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 45.06 % | ||||
| Number Of Shares Shorted | 1.29 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 1.94 X | ||||
| EBITDA | (23.26 M) | ||||
| Net Income | (27.03 M) | ||||
| Cash And Equivalents | 56.72 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.80 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (23.93 M) | ||||
| Short Ratio | 4.27 X | ||||
| Earnings Per Share | (0.51) X | ||||
| Target Price | 7.83 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 135.11 M | ||||
| Total Asset | 45.55 M | ||||
| Retained Earnings | (334.72 M) | ||||
| Working Capital | 21.09 M | ||||
| Current Asset | 78.53 M | ||||
| Current Liabilities | 6.42 M | ||||
| Net Asset | 45.55 M |
About Corvus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corvus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corvus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corvus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Corvus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corvus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Corvus Stock
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.7 | DMAC | DiaMedica Therapeutics | PairCorr |
Moving against Corvus Stock
| 0.83 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Corvus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corvus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corvus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corvus Pharmaceuticals to buy it.
The correlation of Corvus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corvus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corvus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corvus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Corvus Pharmaceuticals Piotroski F Score and Corvus Pharmaceuticals Altman Z Score analysis. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Corvus Stock analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Corvus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corvus Pharmaceuticals. If investors know Corvus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corvus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Corvus Pharmaceuticals is measured differently than its book value, which is the value of Corvus that is recorded on the company's balance sheet. Investors also form their own opinion of Corvus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corvus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corvus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corvus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corvus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corvus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corvus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.